PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
The conversation discusses a user's experiment with using hot water and a dermastamp to reduce hair loss, improve dandruff, and promote new hair growth. The user advises caution and mentions not sharing photos until more progress is visible.
The user is considering switching from a stamp to a pen for hair treatment due to poor results with the stamp. They are concerned about the availability of pen refills and are seeking better outcomes with the pen.
The conversation discusses using tretinoin for hair loss and whether applying SPF on the scalp is necessary if hair covers the treated areas. The user is considering this treatment despite having no completely bald patches.
The user experiences scalp inflammation, especially when oily, despite using treatments like dutasteride, oral minoxidil, RU58841, and nizoral. They recently started cetirizine and are considering benzoyl peroxide wash for relief.
A user is considering combining oral and topical dutasteride to lower scalp DHT more effectively and is seeking advice on this approach. They are thinking about doing a patch test on their mid scalp.
Adding a daily scalp massage with an acupressure device before applying minoxidil can enhance its effects by improving blood circulation, with no side effects. Users are advised to continue microneedling weekly and consider using a derma stamp to avoid scarring.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
PP405 is being discussed as a potential treatment for hair loss, with uncertainty about its effectiveness compared to existing treatments like finasteride, dutasteride, and minoxidil. There is cautious optimism, but its impact on hair transplants remains unclear.
A user shared their positive experience with scalp micropigmentation (SMP) to cover hair thinning and a scar, choosing it over hair transplants due to its non-invasive nature and realistic results. They recommend SMP for those struggling with hair loss, emphasizing the importance of finding a trusted artist.
A 28-year-old male experiencing diffuse thinning and miniaturization around the ears and back has tried finasteride, dutasteride, and both topical and oral minoxidil without success. He is seeking advice on identifying the type of hair loss and next steps since current treatments are ineffective.
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.
Botox injections may be more effective than finasteride for hair growth by reducing scalp tension. The discussion also suggests choosing FUE over FUT due to potential loss of scalp elasticity with FUT.
PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.
Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.
A female user is experiencing severe hair loss, especially at the crown and front, with broken and dull hair despite using Moroccan oil, shea moisture shampoo, and coconut oil. She seeks recommendations for a clinic or doctor as previous doctors attributed the issue to stress but offered no solutions.
User Topher1999 achieved hair regrowth using Dutasteride 3 times a week and microneedling with Dr. Pen Ultima A6 every 2 weeks for 9 months. They believe microneedling is the main reason for hairline gains.
Monthly microneedling combined with low-dose topical dutasteride shows promising results for hair density and thickness with minimal side effects, especially in the frontal area. Despite its effectiveness, it is not widely discussed or used due to availability and cost concerns.
The conversation humorously discusses hair loss treatments, mentioning scalp massage, minoxidil, and the ineffectiveness of devices like the "Gr0wBand." It highlights the role of androgens in hair loss and suggests that increased blood flow from massage may not significantly impact hair growth.
A 24-year-old male experiencing diffused thinning discusses his DHT levels and hair density issues. He has not used finasteride or dutasteride and is considering AR inhibitors.
User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.
A user experimented with applying hot water to their scalp to potentially stimulate hair growth, noting reduced dandruff but uncertain hair loss results. They started this method due to side effects from minoxidil and are considering taking a break to observe changes.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
The user is considering a second hair transplant or scalp micropigmentation to address thinning in the crown area and hide scars from a previous transplant. They have been using finasteride and minoxidil for three years but are concerned about the appearance of their donor area and the effectiveness of scalp micropigmentation.
PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.
A user is using Fluridil for hair loss and is concerned that styling clay and powder might affect the absorption of the treatment. They apply clay in the morning and Fluridil in the evening and are considering switching to a styling powder.
Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.
Using a silicone scalp massager may help with dandruff and potentially improve the absorption of minoxidil and finasteride. The user has noticed peach fuzz growth after using minoxidil for over a month and finasteride for almost a month.
The user is frustrated about not hearing any updates on the HMI-115 trial for hair loss. They are questioning if there will be any updates in the future.